These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36104179)

  • 1. A Pilot Study of Whole-Brain Low-Intensity Pulsed Ultrasound Therapy for Early Stage of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial.
    Shimokawa H; Shindo T; Ishiki A; Tomita N; Ichijyo S; Watanabe T; Nakata T; Eguchi K; Kikuchi Y; Shiroto T; Takahashi J; Yasuda S; Arai H
    Tohoku J Exp Med; 2022 Oct; 258(3):167-175. PubMed ID: 36104179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal treatment conditions for low-intensity pulsed ultrasound therapy for Alzheimer's disease: applications from mice to humans.
    Shindo T; Eguchi K; Monma Y; Kanai H; Yasuda S; Shimokawa H
    J Med Ultrason (2001); 2024 Jul; 51(3):419-427. PubMed ID: 38698287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled pilot trial of low-intensity pulsed ultrasound therapy for refractory angina pectoris.
    Shindo T; Ito K; Ogata T; Kurosawa R; Eguchi K; Kagaya Y; Hanawa K; Hasebe Y; Nishimiya K; Shiroto T; Takahashi J; Okumura Y; Noguchi T; Ozaki Y; Daida H; Hagiwara N; Masuyama T; Chikamori T; Fukumoto Y; Tsujita K; Kanai H; Yasuda S; Shimokawa H
    PLoS One; 2023; 18(6):e0287714. PubMed ID: 37352324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-brain low-intensity pulsed ultrasound therapy markedly improves cognitive dysfunctions in mouse models of dementia - Crucial roles of endothelial nitric oxide synthase.
    Eguchi K; Shindo T; Ito K; Ogata T; Kurosawa R; Kagaya Y; Monma Y; Ichijo S; Kasukabe S; Miyata S; Yoshikawa T; Yanai K; Taki H; Kanai H; Osumi N; Shimokawa H
    Brain Stimul; 2018; 11(5):959-973. PubMed ID: 29857968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance.
    Blivet G; Relano-Gines A; Wachtel M; Touchon J
    J Alzheimers Dis; 2022; 90(2):811-822. PubMed ID: 36189591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-intensity pulsed ultrasound therapy promotes recovery from stroke by enhancing angio-neurogenesis in mice in vivo.
    Ichijo S; Shindo T; Eguchi K; Monma Y; Nakata T; Morisue Y; Kanai H; Osumi N; Yasuda S; Shimokawa H
    Sci Rep; 2021 Mar; 11(1):4958. PubMed ID: 33654156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Low-Intensity Transcranial Pulsed Ultrasound Treatment in a Model of Alzheimer's Disease.
    Tramontin NDS; Silveira PCL; Tietbohl LTW; Pereira BDC; Simon K; Muller AP
    Ultrasound Med Biol; 2021 Sep; 47(9):2646-2656. PubMed ID: 34130881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA).
    Shim Y; Han HJ; Park KW; Kim BC; Park KH; Park MY; Kim HJ; Moon SY; Choi SH; Park KW; Yang DW; Yoon SJ; Kim SY; Youn YC; Choi H; Yoon KE; Cho HJ; Han SH
    J Alzheimers Dis; 2022; 87(1):391-403. PubMed ID: 35275529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
    Henderson ST; Vogel JL; Barr LJ; Garvin F; Jones JJ; Costantini LC
    Nutr Metab (Lond); 2009 Aug; 6():31. PubMed ID: 19664276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-intensity pulsed ultrasound improves symptoms in patients with Buerger disease: a double-blinded, randomized, and placebo-controlled study.
    Mohamad Yusoff F; Kajikawa M; Yamaji T; Kishimoto S; Maruhashi T; Nakashima A; Tsuji T; Higashi Y
    Sci Rep; 2024 Jun; 14(1):13704. PubMed ID: 38871832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.